San Francisco, California — January 12, 2026 — Leads & Copy — Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has released preliminary fourth quarter and full-year 2025 net product revenues, along with data on cash, cash equivalents, restricted cash, and investments as of December 31, 2025.
The announcement was made as part of the company’s presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Sarepta reported total net product revenue of $369.6 million for the fourth quarter and $1.86 billion for the full year. These figures exclude revenue from collaboration, contract manufacturing, or royalties.
Net product revenue for ELEVIDYS totaled $110.4 million for the fourth quarter and $898.7 million for the full year. Sarepta’s PMOs (phosphorodiamidate morpholino oligomers) generated $259.2 million in net product revenue for the fourth quarter and $965.6 million for the full year.
As of December 31, 2025, the company held approximately $953.8 million in cash, cash equivalents, restricted cash, and investments.
“Sarepta faced and overcame challenges in 2025, achieving meaningful pipeline progress and solid performance,” said Doug Ingram, chief executive officer of Sarepta. He noted that the fourth quarter revenue for ELEVIDYS was impacted by the flu season and the rescheduling of six patient infusions into 2026.
Ingram stated that the company intends to exceed the yearly sales floor for ELEVIDYS of $500.0 million. Sarepta will hold off on providing more detailed guidance until the results of its initiatives can be evaluated.
ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy designed to address the genetic cause of Duchenne muscular dystrophy (DMD). It delivers a transgene that codes for the production of ELEVIDYS micro-dystrophin in skeletal muscle and is indicated for ambulatory patients 4 years of age and older with a confirmed mutation in the DMD gene.
Sarepta is focused on precision genetic medicine for rare diseases. The company has a leadership position in Duchenne muscular dystrophy (Duchenne) and is building a portfolio of programs across muscle, central nervous system, and cardiac diseases.
Contact:
Investor Relations
Sarepta Therapeutics, Inc.
ir@sarepta.com
Source: Sarepta Therapeutics, Inc.
